Biogen Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
9,784
- Stock Symbol
-
BIIB
- Investments
-
68
- Share Price
-
$124.76
- (As of Monday Closing)
Biogen General Information
Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Contact Information
Website
www.biogen.comCorporate Office
- 225 Binney Street
- Cambridge, MA 02142
- United States
Corporate Office
- 225 Binney Street
- Cambridge, MA 02142
- United States
Biogen Stock Performance
As of 23-Jun-2025, Biogen’s stock price is $124.76. Its current market cap is $18.3B with 147M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $124.76 | $127.04 | $110.03 - $238.00 | $18.3B | 147M | 1.67M | $10.16 |
Biogen Financials Summary
As of 31-Mar-2025, Biogen has a trailing 12-month revenue of $9.8B.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 24,285,246 | 27,235,101 | 42,918,484 | 41,591,069 |
| Revenue | 9,816,400 | 9,675,900 | 9,835,600 | 10,173,400 |
| EBITDA | 2,628,300 | 2,761,900 | 1,762,000 | 4,267,500 |
| Net Income | 1,479,300 | 1,632,200 | 1,161,100 | 3,046,900 |
| Total Assets | 28,033,100 | 28,049,300 | 26,844,800 | 24,554,100 |
| Total Debt | 6,621,200 | 6,630,300 | 7,338,200 | 6,614,000 |
Biogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biogen Comparisons
Industry
Financing
Details
Biogen Competitors (32)
One of Biogen’s 32 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Galapagos (Biotechnology) | Formerly VC-backed | Mechelen, Belgium | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Moderna | Formerly VC-backed | Cambridge, MA | ||||
| CureVac | Formerly VC-backed | Tubingen, Germany |
Biogen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biogen Patents
Biogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240139487-A1 | Implantable cranial medical device | Pending | 01-Nov-2022 | ||
| AU-2023365490-A1 | Compositions and methods for treating retinitis pigmentosa | Pending | 21-Oct-2022 | ||
| EP-4562018-A1 | Compounds for treating huntington's disease | Pending | 29-Jul-2022 | ||
| EP-4558481-A1 | Emopamil-binding protein inhibitors and uses thereof | Pending | 22-Jul-2022 | ||
| AU-2023308205-A1 | Emopamil-binding protein inhibitors and uses thereof | Pending | 15-Jul-2022 | C07D405/12 |
Biogen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biogen Investments & Acquisitions (68)
Biogen’s most recent deal was a Later Stage VC with Autobahn Therapeutics for . The deal was made on 24-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Autobahn Therapeutics | 24-Jul-2024 | Later Stage VC | Biotechnology | ||
| HI-Bio | 02-Jul-2024 | Merger/Acquisition | Biotechnology | ||
| Reata Pharmaceuticals | 26-Sep-2023 | Merger/Acquisition | Drug Discovery | ||
| Autobahn Therapeutics | 08-Sep-2022 | Later Stage VC | Biotechnology | ||
| Atalanta Therapeutics | 11-Jan-2021 | Early Stage VC | Drug Discovery |
Biogen ESG
Risk Overview
Risk Rating
Updated April, 18, 2025
20.35 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Biogen Exits (35)
Biogen’s most recent exit was on 01-Nov-2018 from Samsung Bioepis. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Samsung Bioepis | 01-Nov-2018 | Completed |
|
||
| Ionis Pharmaceuticals | 11-Jun-2018 | Completed |
|
||
| Solid Biosciences | 30-Mar-2017 | Completed |
|
||
| Ionis Pharmaceuticals | 03-Aug-2016 | Completed |
|
||
| Yumanity Therapeutics | 18-Feb-2016 | Early Stage VC | Completed |
|
Biogen Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AliveGen USA | Thousand Oaks, CA | 2014 | |
| TYSABRI | NC | 2004 | |
| Biogen (Biosimilar Unit) | MA |
Biogen FAQs
-
When was Biogen founded?
Biogen was founded in 1978.
-
Where is Biogen headquartered?
Biogen is headquartered in Cambridge, MA.
-
What is the size of Biogen?
Biogen has 9,784 total employees.
-
What industry is Biogen in?
Biogen’s primary industry is Biotechnology.
-
Is Biogen a private or public company?
Biogen is a Public company.
-
What is Biogen’s stock symbol?
The ticker symbol for Biogen is BIIB.
-
What is the current stock price of Biogen?
As of 23-Jun-2025 the stock price of Biogen is $124.76.
-
What is the current market cap of Biogen?
The current market capitalization of Biogen is $18.3B.
-
What is Biogen’s current revenue?
The trailing twelve month revenue for Biogen is $9.8B.
-
Who are Biogen’s competitors?
Arrowhead Pharmaceuticals, Galapagos (Biotechnology), AbbVie, Moderna, and CureVac are some of the 32 competitors of Biogen.
-
What is Biogen’s annual earnings per share (EPS)?
Biogen’s EPS for 12 months was $10.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
